

Andrea V Margulis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1143492/publications.pdf>

Version: 2024-02-01

41
papers

1,563
citations

430874

18
h-index

315739

38
g-index

45
all docs

45
docs citations

45
times ranked

2610
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa Scale and the RTI item bank. <i>Clinical Epidemiology</i> , 2014, 6, 359.	3.0	325
2	Algorithms to estimate the beginning of pregnancy in administrative databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 16-24.	1.9	154
3	Use of topiramate in pregnancy and risk of oral clefts. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, 405.e1-405.e7.	1.3	130
4	Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. <i>Lancet Rheumatology</i> , The, 2020, 2, e698-e711.	3.9	117
5	Effectiveness of Pediatric Antiretroviral Therapy in Resourceâ€limited Settings: A Systematic Review and Metaâ€analysis. <i>Clinical Infectious Diseases</i> , 2009, 49, 1915-1927.	5.8	107
6	Elevated Risk of Preeclampsia in Pregnant Women With Depression: Depression or Antidepressants?. <i>American Journal of Epidemiology</i> , 2012, 175, 988-997.	3.4	81
7	The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 129.	1.7	62
8	Beginning and duration of pregnancy in automated health care databases: review of estimation methods and validation results. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 335-342.	1.9	56
9	Validation of Cancer Cases Using Primary Care, Cancer Registry, and Hospitalization Data in the United Kingdom. <i>Epidemiology</i> , 2018, 29, 308-313.	2.7	51
10	Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensityâ€score matched cohort in CPRD. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 942-951.	1.9	43
11	Patterns of Prescription of Antidepressants and Antipsychotics Across and Within Pregnancies in a Population-Based UK Cohort. <i>Maternal and Child Health Journal</i> , 2014, 18, 1742-1752.	1.5	43
12	Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e229-e238.	2.0	37
13	Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 900-909.	1.9	35
14	Cardiovascular risk associated with the use of glitazones, metformin and sulfonylureas: meta-analysis of published observational studies. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 14.	1.7	28
15	The Role of Congenital Cytomegalovirus Infection in Adverse Birth Outcomes: A Review of the Potential Mechanisms. <i>Viruses</i> , 2021, 13, 20.	3.3	28
16	Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. <i>PLoS ONE</i> , 2019, 14, e0214180.	2.5	25
17	Triggers of Spontaneous Preterm Delivery â€ Why Today?. <i>Paediatric and Perinatal Epidemiology</i> , 2014, 28, 79-87.	1.7	23
18	Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States. <i>Infectious Diseases and Therapy</i> , 2017, 6, 477-486.	4.0	20

#	ARTICLE	IF	CITATIONS
19	Effects of gestational age at enrollment in pregnancy exposure registries. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 343-352.	1.9	17
20	The Safety of Medications in Pregnant Women: An Opportunity to Use Database Studies. <i>Pediatrics</i> , 2017, 140, .	2.1	16
21	Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis. <i>Drugs - Real World Outcomes</i> , 2017, 4, 139-149.	1.6	15
22	Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study. <i>Pharmacotherapy</i> , 2018, 38, 628-637.	2.6	15
23	Value of Free-text Comments for Validating Cancer Cases Using Primary-care Data in the United Kingdom. <i>Epidemiology</i> , 2018, 29, e41-e42.	2.7	15
24	Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. <i>PLoS ONE</i> , 2018, 13, e0204456.	2.5	15
25	Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 237-247.	1.9	15
26	Determining the predictive value of Read codes to identify congenital cardiac malformations in the UK Clinical Practice Research Datalink. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1233-1238.	1.9	13
27	Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 193-199.	1.9	12
28	Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias. <i>Pharmacotherapy</i> , 2017, 37, 673-683.	2.6	11
29	Ophthalmic nepafenac use in the Netherlands and Denmark. <i>Acta Ophthalmologica</i> , 2017, 95, 509-517.	1.1	8
30	Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 1088-1097.	1.9	7
31	Opportunities and Challenges in Using Epidemiologic Methods to Monitor Drug Safety in the Era of Large Automated Health Databases. <i>Current Epidemiology Reports</i> , 2014, 1, 194-205.	2.4	6
32	Incidence of Common Cancers in Users of Antimuscarinic Medications for Overactive Bladder: A Danish Nationwide Cohort Study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 612-619.	2.5	6
33	Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. <i>Drug Safety</i> , 2021, 44, 899-915.	3.2	6
34	Perinatal pharmacoepidemiology: How often are key methodological elements reported in publications?. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 61-71.	1.9	4
35	Risk Factors for RSV Hospitalization in Healthy Preterm Infants. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 696-696.	2.0	3
36	Drug Safety in Pregnancy: Review of Study Approaches Requested by Regulatory Agencies. <i>Current Epidemiology Reports</i> , 2019, 6, 380-389.	2.4	3

#	ARTICLE	IF	CITATIONS
37	A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. <i>Current Medical Research and Opinion</i> , 2021, 37, 867-877.	1.9	3
38	Improving the Quality of Observational Data: Registries of Validated Outcomes and Other Patient Events. <i>Epidemiology</i> , 2021, 32, 661-663.	2.7	2
39	Reply to Journal Club Roundtable. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 72.	1.3	0
40	Frequentist and Bayesian Meta-Analysis of Risk Factors for Respiratory Syncytial Virus Hospitalization in Preterm Infants. <i>Value in Health</i> , 2016, 19, A174.	0.3	0
41	Proportions of Cancer Cases in Primary Care, Hospital, and Cancer Registry Data Among Patients Treated for Overactive Bladder. <i>Epidemiology</i> , 2019, 30, e8-e9.	2.7	0